Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention

References

• Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244–2247. doi:10.1182/blood-2006-04-013052
   PubMed Web of Science ®Google Scholar
• Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genom. 2007;17:1057–64. doi:10.1097/FPC.0b013e3282f1b2be
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362. doi:10.1056/NEJMoa0809171
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857. doi:10.1001/jama.2009.1232
   PubMed Web of Science ®Google Scholar
• Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):197–215. doi:10.1016/j.jacc.2021.09.005
   PubMedGoogle Scholar
• Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575
   PubMed Web of Science ®Google Scholar
• Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 genotype and clopidogrel therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959–967. doi:10.1002/cpt.2526
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12(16):1521–1537. doi:10.1016/j.jcin.2019.03.034
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–1631. doi:10.1056/NEJMoa1907096
   PubMed Web of Science ®Google Scholar
• Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial. J Am Coll Cardiol. 2018;71(17):1869–1877. doi:10.1016/j.jacc.2018.02.029
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite investigation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(2):181–191. doi:10.1016/j.jcin.2017.07.022
   PubMed Web of Science ®Google Scholar
• Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv. 2021;14(7):739–750. doi:10.1016/j.jcin.2021.01.024
   PubMed Web of Science ®Google Scholar
• Lee SH, Jeong YH, Hong D, et al. Clinical impact of CYP2C19 genotype on clopidogrel-based antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2023;16(7):829–843. doi:10.1016/j.jcin.2023.01.363
   PubMed Web of Science ®Google Scholar
• Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324(8):761–771. doi:10.1001/jama.2020.12443
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–323. doi:10.1038/clpt.2013.105
   PubMed Web of Science ®Google Scholar
• Maroko AR, Doan TM, Arno PS, et al. Integrating social determinants of health with treatment and prevention: a new tool to assess local area deprivation. Prev Chronic Dis. 2016;13:E128. doi:10.5888/pcd13.160221
   PubMed Web of Science ®Google Scholar
• James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2009;157(4):599–605. doi:10.1016/j.ahj.2009.01.003
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale of the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152(4):627–635. doi:10.1016/j.ahj.2006.04.012
   PubMed Web of Science ®Google Scholar
• Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic status and cardiovascular outcomes. Circulation. 2018;137(20):2166–2178. doi:10.1161/CIRCULATIONAHA.117.029652
   PubMed Web of Science ®Google Scholar
• Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524–1534. doi:10.1161/CIRCULATIONAHA.117.029652
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032–2042. doi:10.1056/NEJMoa1908419
   PubMed Web of Science ®Google Scholar